Citizens JMP analyst Roy Buchanan raised the firm’s price target on Cidara Therapeutics (CDTX) to $153 from $66 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics price target raised to $100 from $74 at Needham
- Cidara Therapeutics’ Accelerated Path to BLA Approval and Expanded Market Potential Boosts Buy Rating
- Accelerated Phase 3 Study and Expanded Market Potential Make Cidara Therapeutics a Strong Buy
- Cidara Therapeutics price target raised to $167 from $70 at Guggenheim
- Cidara announced several positive CD388 updates, says H.C. Wainwright